Endovascular management of acute ischemic stroke: Advances in patient and treatment selection

Expert Review of Neurotherapeutics

Volumn 7, Issue 2, 2007, Pages 143-153

  Gupta, Rishi ^a   Jovin, Tudor G ^b  

^a East Lansing   (United States)

^b NONE   (United States)

Author keywords

Acute stroke; Cerebral blood flow; Endovascular therapy; Perfusion imaging; Stents

Indexed keywords

ABCIXIMAB; ACETAZOLAMIDE; DESMOTEPLASE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; PLACEBO; PROUROKINASE; RETEPLASE; TENECTEPLASE; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ADJUVANT THERAPY; BLEEDING; BRAIN ARTERY; BRAIN BLOOD FLOW; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DOSE RESPONSE; DRUG HALF LIFE; HUMAN; MEDICAL INSTRUMENTATION; MONOTHERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCLUSIVE CEREBROVASCULAR DISEASE; PATIENT SELECTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RADIOGRAPHY; REVIEW; STENT; THROMBECTOMY; TREATMENT OUTCOME; ANGIOPLASTY; BRAIN ANGIOGRAPHY; BRAIN ISCHEMIA; CASE REPORT; FEMALE; MIDDLE AGED; NEUROLOGY;

ANGIOPLASTY; BRAIN ISCHEMIA; CEREBRAL ANGIOGRAPHY; CEREBROVASCULAR ACCIDENT; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MIDDLE AGED; NEUROLOGY; PATIENT SELECTION; STENTS; THROMBECTOMY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33847326975     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.7.2.143     Document Type: Review

References (93)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 333(24), 1581-1587 (1995).
2. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 282(21), 2019-2026 (1999).
3. Katzan IL, Hammer MD, Hixson ED, Furlan AJ, Abou-Chebl A, Nadzam DM. Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch. Neurol. 61(3), 346-350 (2004).
4. Alexandrov AV, Molnia CA, Grotta JC et al. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N. Engl. J. Med. 351(21), 2170-2178 (2004).
5. Wolpert SM, Bruckmann H, Greenlee R, Wechsler L, Pessin MS, del Zoppo GJ. Neuroradiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. The rt-PA Acute Stroke Study Group. AJNR Am. J. Neuroradiol. 14(1), 3-13 (1993).
6. Labiche LA, Al-Senani F, Wojner AW, Grotta JC, Malkoff M, Alexandrov AV. Is the benefit of early recanlization sustained at 3 months? A prospective cohort study. Stroke 34(3), 695-698 (2003).
7. Castaigne P, Lhermitte F, Gautier JC, Escourolle R, Derouesne C. Internal carotid artery occlusion: a study of 61 instances in 50 patients with post-morten data. Brain 93(2), 231-258 (1970).
8. Fisher CM, Gore I, Okabe N, White PD. Atherosclerosis of the carotid and vertebral arteries: extracranial and intracranial. J. Neuropathol. Exp. Neurol. 24, 455-476 (1965).
9. Castaigne P, Lhermitte F, Gautier et al. Arterial occlusions in the vertebro-basilar system. A study of 44 patients with postmortem data. Brain 96(1), 133-154 (1973).
10. Lhermitte F, Gautier JC, Derouesne C, Guiraud B. Ischemic accidents in the middle cerebral artery territory: a study of causes in 122 cases. Arch. Neurol. 19(3), 248-256 (1968).
11. Chesebro JH, Knatterud G, Roberts R et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) Trial. Circulation 76(1), 142-154 (1987).
12. Grines CL, Topol EJ, Bates ER, Juni JE, Walton JA Jr, O'Neill WW. Infarct vessel status after intravenous tissue plasminogen activator and acute coronary angioplasty: prediction of clinical outcome. Am. Heart J. 115(1 Pt 1), 1-7 (1988).
13. Gershlick AH, Stephens-Lloyd A, Hughes S et al. Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N. Engl. J. Med. 353(26), 2758-2768 (2005).
14. Booth NA, Robbie LA, Croll AM, Bennett B. Lysis of platelet-rich thrombi: the role of PAI-1. Ann. NY Acad. Sci. 667, 70-80 (1992).
15. Kim EY, Heo JH, Lee SK et al. Prediction of thrombolytic efficacy in acute ischemic stroke using thin-section noncontrast CT. Neurology 67(10), 1846-1848 (2006).
16. Qureshi AI, Siddiqui AM, Kim SH et al. Reocclusion of recanalized arteries during intra-arterial thrombolysis for acute ischemic stroke. AJNR Am. J. Neuroradiol. 25(2), 322-328 (2004).
17. Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 59(6), 862-867 (2002).
18. Hacke W, Donnan G, Fieschi C et al. ATLANTIS Trials Investigators, ECASS Trials Investigators, NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 363(9411), 768-774 (2004).
19. Seitz RJ, Meisel S, Weller P, Junghans U, Wittsack HJ, Siebler M. Initial ischemic event: perfusion-weighted MR imaging and apparent diffusion coefficient for stroke evolution. Radiology 237, 1020-1028 (2005).
20. Toni D, Fiorelli M, Gentile M et al. Progressing neurological deficit secondary to acute ischemic Stroke. A study on predictability, pathogenesis, and prognosis. Arch. Neurol. 52(7), 670-675 (1995).
21. Thijs VN, Adami A, Neumann-Haefelin T, Moseley ME, Marks MP, Albers GW. Relationship between severity of MR perfusion deficit and DWI lesion evolution. Neurology 57(7), 1205-1211 (2001).
22. Tong DC, Yenari MA, Albers GW, O'Brien M, Marks MP, Moseley ME. Correlation of perfusion- and diffisuoin-weighted MRI with NIHSS in acute (<6.5 hour) ischemic stroke. Neurology 50(4), 864-870 (1998).
23. Barber PA, Demchuk AM, Zhang J, Buchan AM. Validity and reliability of a quantitative compute tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet 355(9216), 1670-1674 (2000).
24. Hill MD, Rowley HA, Adler F et al. PROACT II Investigators. Selection of acute ischemic stroke patients for intra-arterial thrombolysis with pro-urokinase by using ASPECTS. Stroke 34(8), 1925-1931 (2003).
25. Hill MD, Demchuk AM, Tomsick TA, Palesch YY, Broderick JP. Using baseline CT scan to select acute stroke patients for IV-IA therapy. AJNR Am. J. Neuroradiol. 27(8), 1612-1616 (2006).
26. Wintermark M, Flanders AE, Velthius B et al. Perfusion-CT assessment of infarct core and penumbra. Receiver operating characteristic curve analysis in 130 patients suspected of acute hemispheric stroke. Stroke 37(4), 979-985 (2006).
27. Gupta R, Yonas H, Goldstein S et al. Reduced pretreatment ipsilateral middle cerebral artery cerebral blood flow is predictive of symptomatic hemorrhage post intra-arterial thrombolysis in patients with middle cerebral artery occlusion. Stroke. 37(10), 2526-2530 (2006).
28. Jovin TG, Gupta R, Horowitz MB et al. Pre-treatment ipsilateral regional cortical blood flow influences vessel recanalization in intra-arterial thrombolysis for MCA occlusion. AJNR Am. J. Neuroradiol. 28(1), 164-167 (2007).
29. Jovin TG, Yonas H, Gebel JM et al. The cortical ischemic core and not the consistently present penumbra is a determinant of clinical outcome in acute middle cerebral artery occlusion. Stroke 34(10), 2426-2433 (2003).
30. Hacke W, Albers G, Al-Rawi Y et al.; for The DIAS Study Group. The Desmoteplase in Acute Ischemic stroke Trial (DIAS). A Phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 36(1), 66-73 (2005).
31. Furlan AJ, Eyding D, Albers GW et al. Dose escalation of desmoteplase for acute ischemic stroke (DEDAS). Evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 37(5), 1227-1231 (2006).
32. Shih LC, Saver JL, Alger JR et al. PerfusionHweighted magnetic resonance imaging thresholds identifying core, irreversibly infarcted tissue. Stroke 34(6), 1425-1430 (2003).
33. Albers GW, Thijs VN, Wechsler L et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the Diffusion and pErFusion imaging evaluation for Understanding Stroke Evolution (DEFUSE) study. Ann. Neurol. 60(5), 508-517 (2006).
34. Guadagno JV, Warburton EA, Aigbirhio FI et al. Does the acute diffusion-weighted imaging lesion represent penumbra as well as core? A combined PET/MRI voxel-base study. J. Cereb. Blood Flow Metab. 24(11), 1249-1254 (2004).
35. Furlan A, Higashida R, Wechsler L et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA 282(21), 2003-2011 (1999).
36. Pillai JJ, Lanzieri CF, Trinidad SB, Tarr RW, Sunshine JL, Lewin JS. Initial angiographic appearance of intracranial vascular occlusions in acute stroke as a predictor of outcome of thrombolysis: initial experience. Radiology 218(3), 733-738 (2001).
37. Arnold M, Schroth G, Nedeltchev K et al. Intra-arterial thrombolysis in 100 patients with acute stroke due to middle cerebral artery occlusion. Stroke 33(7), 1828-1833 (2002).
38. Edwards MT, Murphy MM, Geraghty JJ, Wulf JA, Konzen JP. Intra-arterial cerebral thrombolysis for acute ischemic stroke in a community hospital. AJNR Am. J. Neuroradiol. 20, 1682-1687 (1999).
39. Suarez JI, Sunshine JL, Tarr R et al. Predictors of clinical improvement, angiographic recanalization, and intracranial hemorrhage after intra-arterial thrombolysis for acute ischemic stroke. Stroke. 30(10), 2094-2100 (1999).
40. Jahan R, Duckwiler GR, Kidwell CS et al. Intraarterial thrombolysis for treatment of acute stroke: experience in 26 patients with long-term follow-up. AJNR Am. J. Neuroradiol. 20(7), 1291-1299 (1999).
41. Verstraete M. Third-generation thrombolytic drugs. Am. J. Med. 109, 52-58 (2000).
42. Qureshi AI, Ali Z, Suri MF et al. Intra-arterial third generation recombinant tissue plasminogen activator (reteplase) for acute ischemic stroke. Neurosurgery 49(1), 41-50 (2001).
43. Qureshi AI, Siddqui AM, Kim SH et al. Reocclusion of recanalized arteries during intra-arterial thrombolysis for acute ischemic stroke. AJNR Am. J. Neuroradiol. 25(2), 322-328 (2004).
44. Qureshi AI, Harris-Lane P, Kirmani JF et al. Intra-arterial reteplase and intravenous abciximab in patients with acute ischemic stroke: An open-label, dose ranging, Phase I study. Neurosurgery 59(4) 789-796 (2006) .
45. Smalling RW. Molecular biology of plasminogen activators: what are the clinical implications of drug design? Am. J. Cardiol. 78(12A), 2-7 (1996).
46. Tanswell P, Modi N, Combs D, Danays T. Pharmacokinetics and pharmoacodynamics of tenecteplase in fibrinolytic therapy for acute myocardial infarction. Clin. Pharmacokinet. 41(15), 1229-1245 (2002).
47. Lum C, Stys PK, Hogan MJ, Nguyen TB, Srinivasan A, Goyal M. Acute anterior circulation stroke: recanalization using clot angioplasty. Can. J. Neurol .Sci. 33, 217-222 (2006).
48. Lapchak PA, Araujo DM, Zivin JA. Comparison of tenecteplase with alteplase on clinical rating scores following small clot embolic strokes in rabbits. Exp. Neurol. 185(1), 154-159 (2004).
49. Haley EC, Lyden PD, Johnston KC, Hemmen TM, for the TNK in Stroke Investigators. A pilot-dose escalation safety study of tenecteplase in acute ischemic stroke. Stroke 36(3), 607-612 (2005).
50. Krätzschmar J, Haendler B, Langer G et al. The plasminogen activator family from the salivary gland of the vampire bat Desomodus rotundus: cloning and expression. Gene 105, 229-237 (1991).
51. Liberatore GT, Samson A, Bladin C, Schleuning WD, Medcalf RL. Vampire bat salivary plasminogen activator (desmoteplase) - a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke 34(2), 537-543 (2003).
52. Tsirka S, Rogove AD, Strickland S. Neuronal cell death and tPA. Nature 384(6605), 123-124 (1996).
53. Abciximab Emergent Stroke Treatment Trial (AbESTT) Investigators. Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized Phase 2 trial. Stroke 36, 880-890 (2005).
54. Zhang L, Zhang ZG, Zhang C, Zhang RL, Chopp M. Intravenous administration of a GP IIb/IIIa receptor antagonist extends the therapeutic window of intra-arterial tenecteplase-tissue plasminogen activator in rat stroke model. Stroke. 35(12), 2890-2895 (2004).
55. Seitz RJ, Hamzavi M, Junghans U, Ringleb PA, Schranz C, Siebler M. Thrombolysis with recombinant tissue plasminogen activator and tirofiban in stroke: preliminary observations. Stroke 34(8), 1932-1935 (2003).
56. Seitz RJ, Meisel S, Moll M, Wittsack HJ, Junghans U, Siebler M. The effect of combined thrombolysis with rtPA and tirofiban on ischemic brain lesions. Neurology 62(11), 2110-2112 (2004).
57. Straub S, Junghans U, Jovanovic V, Wittsack HJ, Seitz RJ, Siebler M. Systemic thrombolysis with recombinant tissue plasminogen activator and tirofiban in acute middle cerebral artery occlusion. Stroke 35(3), 705-709 (2004).
58. Gupta R, Vora NA, Horowitz MB et al. Multimodal reperfusion therapy for acute ischemic stroke: factors predicting vessel recanalization. Stroke 37(4), 986-990 (2006).
59. Ernst R, Pancioli A, Tomsick T et al. Combined intravenous and intra-arterial recombinant tissue plasminogen activator in acute ischemic stroke. Stroke 31(11), 2552-2557 (2000).
60. Suarez JI, Zaidat OO, Sunshine JL, Tarr R, Selman WR, Landis DM. Endovascular administration after intravenous infusion of thrombolytic agengts for the treatment of patients with acute ischemic strokes. Neurosurgery 50(2), 251-260 (2002).
61. Zaidat OO, Suarez JI, Santillan C et al. Response to intra-arterial and combined intravenous and intra-arterial thrombolytic therapy in patients with distal internal carotid artery occlusion. Stroke 33, 1821-1827 (2002).
62. Lee KY, Kim DI, Kim SH et al. Sequential combination of intravenous recombinant tissue plasminogen activator and intra-arterial urokinase in acute ischemic stroke. AJNR Am. J. Neuroradiol. 25(9), 1470-1475 (2004).
63. Sekoranja L, Loulidi J, Yilmaz H et al. Intravenous versus combined (intravenous and intra-arterial) thrombolysis in acute ischemic stroke. A transcranial color-coded duplex sonography-guided pilot study. Stroke 37(7), 1805-1809 (2006).
64. The IMS Study Investigators. Combined intravenous and intra-arterial recanalizaion for acute ischemic stroke: The Interventional Management of Stroke Study. Stroke 35, 904-912 (2004).
65. Lewandowski CA, Frankel M, Tomsick TA et al. Combined intravenous and intraarterial t-PA versus intra-arterial therapy of acute ischemic stroke. Emergency Management of Stroke (EMS) Bridging Trial. Stroke 30, 2598-2605 (1999).
66. Pierre Gobin Y, Starkman S, Duckwiler GR et al. MERCI 1. A Phase 1 study of Mechanical Embolus Removal in Cerebral Ischemia. Stroke 35(12), 2848-2854 (2004).
67. Smith WS, Sung G, Starkman S et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke. Results of the MERCI trial. Stroke 36(7), 1432-1440 (2005).
68. Tomsick TA. Mechanical embolus removal. A new day dawning. Stroke 36(7), 1439-1440 (2005).
69. Smith WS, for the Multi MERCI Investigators. Safety of mechanical thrombectomy and intravenous tissue plasminogen activator in acute ischemic stroke. Results of the multi Mechanical Embolus Removal in Cerebral Ischemia (MERCI) trial, Part I. AJNR Am. J. Neuroradiol. 27(6), 1177-1182 (2006).
70. Nakano S, Iseda T, Yoneyama T, Kawano H, Wakisaka S. Direct percutaneous transluminal angioplasty for acute middle cerebral artery trunk occlusion: an alternative option to intra-arterial thrombolysis. Stroke 33, 2872-2876 (2002).
71. Ringer AJ, Qureshi AI, Fessler RD, Guterman LR, Hopkins LN. Angioplasty of intracranial occlusion resistant to thrombolysis in acute ischemic stroke. Neurosurgery 48(6), 1282-1288 (2001).
72. Tsai FY, Berberian B, Matovich V, Lavin M, Alfieri K. Percutaneous transluminal angioplasty adjunct to thrombolysis for acute middle cerebral artery rethrombosis. AJNR Am. J. Neuroradiol. 15(10), 1823-1829 (1994).
73. Gupta R, Jovin TG, Tayal A, Horowitz MB. Urgent stenting of the M2 (superior) division of the middle cerebral artery after systemic thrombolysis in acute stroke. AJNR Am. J. Neuroradiol. 27(3), 521-523 (2006).
74. Levy EI, Ecker RD, Horowitz MB et al. Stent-assisted intracranial recanalization for acute stroke: early results. Neurosurgery 58, 458-463 (2006).
75. Balow J, Alter M, Resch JA. Cerebral thromboembolism: a clinical appraisal of 100 cases. Neurology 16, 559-564 (1966).
76. Pessin MS, Duncan GW, Mohr JP, Poskaner DC. Clinical and angiographic features of carotid transient ischemic attacks. N. Engl. J. Med. 296, 358-362 (1977).
77. Grubb RL Jr, Derdeyn CP, Fritsch SM et al. Importance of hemodynamic factors in the prognosis of symptomatic carotid occlusion. JAMA 280, 1055-1060 (1998).
78. Derdeyn CP, Grubb RL Jr, Powers WJ. Cerebral hemodynamic impairment: methods of measurement and association with stroke risk. Neurology 53, 251-259 (1999).
79. Eckstein HH, Schumacher H, Klemm K et al. Emergency carotid endarterectomy. Cerebrovasc. Dis. 9, 270-281 (1999).
80. Aleksic M, Rueger MA, Lehnhardt FG et al. Primary stroke unit treatment followed by very early carotid endarterectomy for carotid artery stenosis after acute stroke. Cerebrovasc. Dis. 22, 276-281 (2006).
81. Jovin TG, Gupta R, Uchino K et al. Emergent stenting of extracranial internal carotid artery occlusion in acute stroke has a high revascularization rate. Stroke 36(11), 2426-2430 (2005).
82. Latour LL, Kang DW, Ezzeddine MA, Chalela JA, Warach S. Early blood-brain barrier disruption in human focal brain ischemia. Ann. Neurol. 56(4), 468-477 (2004).
83. Larrue V, von Kummer R, Müller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator. A secondary analysis of the European-Australian Acute Stroke Study (ECASS II). Stroke 32, 438-441 (2001).
84. The ATLANTIS, ECASS, and NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS and NINDS rt-PA stroke trials. Lancet 363, 768-774 (2004).
85. Larrue V, Von Kummer R, Del Zoppo G, Bluhmki E. Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. Stroke 28, 957-960 (1997).
86. Trouillas P, von Kummer R. Classification and pathogenesis of cerebral hemorrhages after thrombolysis in ischemic stroke. Stroke 37, 556-561 (2006).
87. Molina CA, Alvarez-Sabin J, Montaner J et al. Thombolysis-related hemorrhagic infarction: a marker or reperfusion, reduced infarct size, and improved outcome in patients with proximal middle cerebral artery occlusion. Stroke 33, 1551-1556 (2002).
88. Trouillas P, Derex L, Phillippeau F et al. Early fibrinogen degradation coagulopathy is predictive of parenchymal hematoma in cerebral rt-PA thrombolysis: a study of 157 cases. Stroke 35, 1323-1328 (2004).
89. Ueda T, Hatakeyama T, Kumon Y, Sakaki S, Uraoka T. Evaluation of risk of hemorrhagic transformation in local intra-arterial thrombolysis in acute ischemic stroke by SPECT. Stroke 25, 298-303 (1994).
90. Gupta R, Yonas H, Gebel J et al. Reduced pretreatment ipsilateral middle cerebral artery cerebral blood flow is predictive of symptomatic hemorrhage post-intra-arterial thrombolysis in patients with middle cerebral artery occlusion. Stroke 37(10), 2526-2530 (2006).
91. Khatri P, Broderick JP, Khoury JC, Carrozella, Tomsick T, for the IMS-1 and 2 Investigators. Microcatheter contrast injections during intra-arterial thrombolysis increase intracranial hemorrhage risk. Stroke 37, 622 (2006).
92. NIH. Interventional Management of Stroke (IMS) III Trial www.clinicaltrials.gov/ct/show/NCT003594 24 (Accessed October 2006)
93. US FDA. Wingspan stent system and gateway PTA balloon catheter: summary of safety and probable benefit, August 3, 2005 www.fda.gov/cdrh/pdf5/h050001b. pdf (Accessed September 2006)